Age‐dependent effect of targeted temperature management on outcome after cardiac arrest. (8th October 2018)

• Record Type: Journal Article
• Authors: Wallmüller, Christian; Spiel, Alexander; Sterz, Fritz; Schober, Andreas; Hubner, Pia; Stratil, Peter; Testori, Christoph
• Is Part Of: European journal of clinical investigation. Volume 48:Number 12(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-10-08
• Subjects: cardiopulmonary resuscitation -- induced hypothermia -- prognosis -- resuscitation -- survival; Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.13026
• Languages: English
• ISSNs: 0014-2972

Abstract

Abstract: Background: In elder patients after out‐of‐hospital cardiac arrest, diminished neurologic function as well as reduced neuronal plasticity may cause a low response to targeted temperature management (TTM). Therefore, we investigated the association between TTM (32‐34°C) and neurologic outcome in cardiac arrest survivors with respect to age. Material and Methods: This retrospective cohort study included patients 18 years of age or older suffering a witnessed out‐of‐hospital cardiac arrest with presumed cardiac cause, which remained comatose after return of spontaneous circulation. Patients were a priori split by age into four groups (<50 years (n = 496); 50‐64 years (n = 714); 65‐74 years (n = 395); >75 years (n = 280)). Subsequently, within these groups, patients receiving TTM were compared to those not treated with TTM. Results: Out of 1885 patients, 921 received TTM for 24 hours. TTM was significantly associated with good neurologic outcome in patients <65 years of age whereas showing no effect in elders (65‐74 years: OR: 1.49 (95% CI: 0.90‐2.47); > 75 years: OR 1.44 (95% CI 0.79‐2.34)). Conclusion: In our cohort, it seems that TTM might not be able to achieve the same benefit for neurologic outcome in all age groups. Although the results of this study should be interpreted with caution, TTM was associated with improved neurologic outcome only in younger individuals, patients with 65 years of age or older did not benefit from this treatment.